Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Operating Margin: 2022-2025

Historic Operating Margin for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Sep 2025 value amounting to 8.59%.

  • Arcutis Biotherapeutics' Operating Margin rose 9588.00% to 8.59% in Q3 2025 from the same period last year, while for Sep 2025 it was -12.03%, marking a year-over-year increase of 11913.00%. This contributed to the annual value of -65.33% for FY2024, which is 33916.00% up from last year.
  • Arcutis Biotherapeutics' Operating Margin amounted to 8.59% in Q3 2025, which was up 147.93% from -17.93% recorded in Q2 2025.
  • Arcutis Biotherapeutics' Operating Margin's 5-year high stood at 3,407.40% during Q1 2022, with a 5-year trough of -14,448.00% in Q3 2022.
  • In the last 3 years, Arcutis Biotherapeutics' Operating Margin had a median value of -87.29% in 2024 and averaged -452.24%.
  • Over the last 5 years, Arcutis Biotherapeutics' Operating Margin had its largest YoY gain of 1,432,499bps in 2023, and its largest YoY loss of 614,976bps in 2023.
  • Over the past 4 years, Arcutis Biotherapeutics' Operating Margin (Quarterly) stood at -2,310.84% in 2022, then spiked by 185,861bps to -452.23% in 2023, then soared by 44,154bps to -10.70% in 2024, then soared by 9,588bps to 8.59% in 2025.
  • Its Operating Margin stands at 8.59% for Q3 2025, versus -17.93% for Q2 2025 and -37.25% for Q1 2025.